(Q38379114)

English

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.

scientific article published on 23 July 2016

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Philippe L. Bedard

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

J E Grilley-Olson

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

A Fasolo

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

M Cornfeld

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

L Cartee

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

A R Abdul Razak

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

L-A Stayner

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Y Wu

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

R Greenwood

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

R Singh

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

C B Lee

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

J Bendell

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

H A Burris

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

G Del Conte

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

C Sessa

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

J R Infante

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

23 July 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

740-749

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27450049%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Circulating mutant DNA to assess tumor dynamics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0377-0

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38379114&oldid=2201635549"